Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
The long-serving Chair, Barry Clare, who has been instrumental to Evgen since its 2007 foundation and was a key player during its 2015 IPO, is set to retire soon. Taking his place on a temporary basis is Dr. Susan Foden, the firm’s senior independent director.
CEO Dr. Huw Jones expressed, “We’re immensely grateful for Barry’s steadfast commitment and guidance to Evgen over the years. We extend our best wishes for his next chapter.” He continued, “We’re confident in Susan Foden’s capabilities, given her extensive biotech experience, as she steps up as our interim chair. Our hunt for a permanent chair is in progress.”
With a remarkable track record from her roles at Vectura, BerGenBio AS, BTG (LSE: BTG), and Neurocentrx Ltd, Foden is expected to bring immense value to her new role.
In addition, the organization has brought on board Toni Hänninen as the provisional chief financial officer, filling the void left by Richard Moulson’s retirement in July. Hänninen, boasting over 20 years of expertise and a former CFO role at Faron Pharmaceuticals, is anticipated to be a key asset. “Toni’s extensive experience, especially in the AIM market, is just what we need as we transition to our next growth stage,” stated CEO Jones.
